PDB31 Health Care Resource Use And Costs In Patients With Type 2 Diabetes Mellitus After Treatment Initiation With Saxagliptin Or Sitagliptin  by Kaltenboeck, A. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A161 
 
 
was defined as achieving HbA1c below 7% without weight gain and with no 
hypoglycaemic events in 26 weeks. With the assumption that a payer would be 
interested in paying only for successfully treated patients, cost of control was 
subsequently defined as the price per patient achieving the composite endpoint. 
The relevant comparator drugs, glimepiride, rosiglitazone and insulin glargine, 
were defined as those found both in the ‘Liraglutide Effect and Action in 
Diabetes’ clinical trial programme and on the China national drug 
reimbursement list. The number needed to treat (NNT) for patients achieving the 
composite endpoint at week 26 was also investigated. Costs of drug, needle and 
self-monitoring blood glucose were accounted based on the marketed retail price 
published by National Development and Reform Commission in 2012 Chinese 
value. RESULTS: The NNT for patients on liraglutide 1.2mg was 3.1 for achieving 
the composite endpoint, compared to between 6.7 and 16.7 for the three 
comparator drugs. This lead to the cost per successfully treated patient to be 
between 17% and 68% higher with glimepiride, insulin glargine and rosiglitazone 
compared to liraglutide 1.2mg in China. CONCLUSIONS: By assessing the NNT to 
achieve HbA1c below 7% with no weight gain and no hypoglycaemic events and 
the cost per patient achieving this composite endpoint, liraglutide 1.2mg was a 
cost-saving approach for T2DM patients in comparison with glimepiride, insulin 
glargine and rosiglitazone in a Chinese setting.  
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OBJECTIVES: Compare health care resource use and costs in patients with type 2 
diabetes mellitus (T2DM) treated with saxagliptin or sitagliptin in the 6 months 
following treatment initiation. METHODS: Patients with T2DM treated with 
saxagliptin (N=13,929) or sitagliptin (N=36,813) in 2010 or later were identified in 
the Truven MarketScan database of commercially insured beneficiaries. Patients 
were required to have no claims of saxagliptin or sitagliptin in the 6 months 
prior to treatment initiation, ≥6 months of continuous eligibility before and after 
initiation (baseline and study period, respectively), and be 18 or older. 
Demographic characteristics and comorbidities were evaluated in the baseline 
period. All-cause and diabetes-related resource use and costs were evaluated 
during the study period. Chi-squared and Wilcoxon rank sum tests assessed 
differences in resources use rates and costs. GLM regression with a log link and 
gamma distribution estimated the treatment effect on study period costs, 
adjusting for baseline characteristics and costs. RESULTS: During the study 
period, compared with sitagliptin patients, saxagliptin patients experienced 
lower rates of all-cause hospitalization, emergency department visits, and other 
medical visits (7.2% vs. 10.6%, 14.1% vs. 17.5%, and 67.0% vs. 70.4%, respectively; 
p<0.001). All-cause medical and total costs were lower for saxagliptin patients 
than sitagliptin patients ($4,555 vs. 5,921; $7,346 vs. $8,797; all p<0.001). 
Substantial costs were attributable to hospitalizations, which were less costly for 
saxagliptin patients ($1,477 vs. $1,992; p<0.001). Diabetes-related medical and 
total costs were also significantly lower for saxagliptin patients ($1,084 vs. $1,454; 
$2,445 vs. $2,828; all p<0.001). After adjusting for baseline characteristics, 
significant differences in medical and total costs persisted (all-cause: $5,073 vs. 
$5,535; $7,802 vs. $8,302; diabetes related: $1,149 vs. $1,387; $2,510 vs. $2,772; all 
p<0.001). CONCLUSIONS: Patients initiating treatment with saxagliptin had 
lower resource use and costs in a 6-month follow-up period than patients 
initiating with sitagliptin.  
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OBJECTIVES: To compare annual costs between diabetic macular edema (DME), 
diabetic retinopathy (DR), and diabetes on the direct and indirect costs of US 
employees versus controls without diabetes. METHODS: Analysis of 2001-2012 
administrative claims from the HCMS Reference Database which contains 
anonymous data from >20 geographically-dispersed US employers (1.7 million+ 
employees) including manufacturing, insurance, retail, transportation, 
telecommunications. Employees with DME, DR and Diabetes were identified by 
ICD-9 codes. For DME/DR subjects, the index date was the date of the initial 
claim, and for the other cohorts, the average of DME/DR index dates. All subjects 
were required to have ≥12 months follow-up post index date. Cohorts were 
compared using two-part regression (logistic then generalized linear) models 
controlling for demographics and job-related information. Only subjects eligible 
for a benefit were included in the models for that benefit. All annual direct and 
indirect cost outcomes were inflation-adjusted to 2012 by the appropriate CPI 
index. RESULTS: The analysis identified 426,549 employees (DME=528; DR=1441; 
Diabetes=18,639; Controls=405,931). Medical costs for the cohorts were: 
DME=$12,125; DR=$13,547; Diabetes=$6,815; Controls=$3,326; Rx costs were: 
DME=$3,338; DR=$3,733; Diabetes=$2,502; Controls=$849. Medical and Rx costs 
were significantly different between all cohorts (P<0.0001) except DME-vs-DR. 
Indirect components: Sick Leave: DME=$1009; DR=$924; Diabetes=$830; 
Controls=$606; Short-term Disability: DME=$705; DR=$760; Diabetes=$483; 
Controls=$259; Long-term Disability: DME=$136; DR=$240; Diabetes=$66; 
Controls=$29; Workers’ Compensation: DME=$119; DR=$75; Diabetes=$229; 
Controls=$189. All DR-vs-Controls and Diabetes-vs-Controls comparisons were 
significant (P<0.03). Sick Leave and Short-term Disability for the other cohort 
pairs were also significant (P<0.05), except DME-vs-DR. Workers’ Compensation 
was significantly lower for DME-vs-Diabetes and DR-vs-Diabetes. CONCLUSIONS: 
This analysis shows the significant impact of DME and DR on employee direct 
and indirect costs across a variety of benefits. Overall employees with Diabetes 
were $5667 more expensive than Controls, and DME and DR resulted in 
incremental costs of $6507 and $8354 more than those with Diabetes, 
respectively.  
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OBJECTIVES: Strict control of glycemia in diabetic patients is impeded by the risk 
of hypoglycemia, especially when insulin is used. However, not all insulins have 
the same risk of hypoglycemia. The aim of this study was to study the cost of 
insulin related hypoglycemia requiring hospitalization (at least one overnight 
stay) in type-1 and 2 diabetes in Belgium. METHODS: A retrospective database 
study was conducted using the longitudinal IMS Hospital Disease Database (HDD 
2009), covering 34.3% of Belgian hospital beds. In this database hypoglycemic 
events can be identified based on ICD-9 codes (Diabetes hypoglycemic 
coma/insulin coma: 250.3; Diabetic hypoglycemia/hypoglycemic shock: 250.8; 
Anti-diabetic agent poisoning and adverse events: E932.3, 962.3). Number of stays 
for hypoglycemia, average length of stay (LOS) and on intensive care (ICU), in 
hospital mortality, re-hospitalizations for hypoglycemia and costs were 
estimated using SAS software. RESULTS: In the HDD 2291 patients were 
hospitalized for hypoglycemia due to insulin. In 2009, each patient had on 
average 1.12 hospitalizations. Eighty-five percent of those stays were in patients 
older than 55. The average LOS was 20.69 days (with 0.31 days on ICU) strongly 
driven by stays in the population >55 years (13 vs. 22 days; p<0.0001). Mortality 
during hospitalization was 6.78% driven by the age group older than 65 (3.49% vs. 
8.20%; p<0.0001). The average cost of a hospitalization was €11,066 [€10,077-
€11,359]. CONCLUSIONS: Hospitalizations for hypoglycemia due to insulin are 
expensive and result in an important in hospital mortality. Especially in the 
older age (>55), the costs for the health care payer are high due to extensive LOS. 
Interventions that can help reduce the risk of hypoglycemia, and as a 
consequence the burden on hospitals and society, without compromising 
glycemic control will help further improve diabetes management.  
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OBJECTIVES: To estimate the trend in direct and indirect costs among patients 
with diabetes in urban China from 2009 to 2011. METHODS: Data were obtained 
from the 2009-2011 Urban Resident Basic Medical Insurance (URBMI) household 
survey in 9 cities. Households were sampled to be representative of all 
households in these cities. Patients who self-reported to have a diabetes 
diagnosis were included. Annual costs per patient were estimated from the 
societal perspective, which included direct medical, direct non-medical and 
indirect costs. Direct medical costs included outpatient service, outpatient drug 
and inpatient costs. Outpatient service and drug costs were reported for the past 
2 weeks and extrapolated to 1 year. Inpatient costs were estimated based on the 
number of hospitalizations during the past year and costs for the most recent 
hospitalization. Direct non-medical costs included transportation, 
accommodation costs, etc. Indirect costs due to absenteeism were estimated for 
employed patients based on mean annual national wage of urban employees in 
China. All costs were inflated and converted to 2011 USD. RESULTS: A total of 
3,253 patients with self-reported diabetes diagnosis (N=1,078 in 2009, 1,114 in 
2010 and 1,061 in 2011) were included, with 49.1% female and a mean age of 64.0 
years. Mean annual direct medical costs were $1,303.2, $1,460.1 and $2,072.0 in 
2009, 2010 and 2011, respectively. Mean outpatient drug costs were $565.8, $683.7 
and $1034.5 in the three years, respectively, accounting for 43.4% to 49.9% of the 
direct medical costs. Insurance covered 42.8% to 45.5% of the direct medical 
costs. Mean annual direct non-medical costs were $111.9, $204.3 and $619.6 in 
2009, 2010 and 2011, respectively (P=0.224). The corresponding indirect costs 
were $135.0 (N=199), $201.3 (N=172) and $180.3 (N=167). CONCLUSIONS: Direct 
medical costs, outpatient drug costs and direct non-medical costs of diabetes 
increased numerically from 2009-2011 in urban China .  
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OBJECTIVES: To estimate medical expenditure for people with diabetes in Urban 
Employee Basic Medical Insurance (UEBMI) program in 2011 in Beijing, China. 
METHODS: Claims data from Beijing UEBMI database during 2010.10.01 to 
2011.09.30 was extracted with the criterion of people diagnosed with “diabetes 
mellitus” during this period. The Sum_All Medical method was used for 
